PURPOSERadiation dose escalation for locally advanced non–small cell lung cancer (LA-NSCLC) has been challenged by toxicity concerns. The Scandinavian phase III multicenter dose-escalation trial NARLA...

There is growing interest in reirradiation (reRT) for new or recurrent malignancies in previously irradiated regions.1-25 Historically, reRT to the same or an adjacent site has been used relatively sp...

Leeds Cancer Centre is bringing a new era of hope to cancer patients with the introduction of MRI-only radiotherapy.

During 2000–20, NHS coverage of new drugs displaced more population health than it generated. Our results highlight the inherent trade-offs between individuals who directly benefit from new drugs and those who forgo health due to the reallocation of resources towards new drugs.

ALT: a countdown clock with the number 10 in the center

Many cancer drugs approved through the FDA's accelerated approval pathway do not offer any survival benefit to patients. In this study, individuals expressed strong preferences for certainty that a cancer drug would offer survival benefit. Some individuals also expressed a higher willingness to wait for greater certainty than would be necessary to assess the survival benefit (over progression-free survival benefit) of most cancer drugs used in the metastatic setting.